Nevada Medicaid spending on GLP-1 drugs
How much did Nevada Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?
Pharmacies were reimbursed at least $81.9 million for GLP-1 drugs paid through Nevada Medicaid in 2025, across at least 70,939 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 84 rows of 279, so these figures are floors.
Pharmacies were reimbursed at least $24.9 million for GLP-1 drugs paid through Nevada Medicaid in 2026 (quarter 1 only, as posted so far), across at least 19,396 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 27 rows of 88, so these figures are floors.
By year and ingredient
| 2020 | at least $1,439,397 | No data | at least $3,187,734 | at least $9,993,307 | at least $663,590 | at least $54,991 | at least $621,941 | Suppressed | at least $15,960,961 |
| 2021 | at least $6,945,085 | No data | at least $2,866,402 | at least $17,519,210 | at least $356,027 | at least $10,911 | at least $564,856 | Suppressed | at least $28,262,491 |
| 2022 | at least $12,704,308 | at least $298,974 | at least $2,794,439 | at least $24,235,671 | at least $296,705 | Suppressed | at least $370,859 | Suppressed | at least $40,700,957 |
| 2023 | at least $18,436,069 | at least $3,007,654 | at least $1,224,668 | at least $24,592,164 | at least $109,064 | Suppressed | at least $287,381 | Suppressed | at least $47,657,000 |
| 2024 | at least $39,256,994 | at least $12,212,114 | at least $655,848 | at least $10,847,481 | at least $250,789 | No data | at least $253,243 | Suppressed | at least $63,476,470 |
| 2025 | at least $51,018,617 | at least $24,208,669 | at least $508,870 | at least $5,962,540 | at least $31,868 | No data | at least $137,831 | Suppressed | at least $81,868,395 |
| 2026 (Q1) | at least $14,001,637 | at least $9,177,470 | at least $83,502 | at least $1,620,007 | Suppressed | No data | at least $24,828 | Suppressed | at least $24,907,445 |
By product, 2025
| Ozempic | at least $47,787,958 | at least 42,402 | 2 of 26 |
| Rybelsus | $2,112,252 | 1,671 | 0 of 24 |
| Wegovy | at least $1,118,407 | at least 876 | 14 of 40 |
| Mounjaro | at least $23,829,161 | at least 19,176 | 7 of 55 |
| Zepbound | at least $379,508 | at least 364 | 19 of 31 |
| Liraglutide (generic name listing) | at least $508,870 | at least 1,792 | 12 of 34 |
| Victoza | Suppressed | Suppressed | 10 of 10 |
| Trulicity | at least $5,962,540 | at least 4,482 | 5 of 37 |
| Bydureon | at least $31,868 | at least 28 | 3 of 5 |
| Byetta | Suppressed | Suppressed | 1 of 1 |
| Exenatide (generic name listing) | Suppressed | Suppressed | 3 of 3 |
| Soliqua | at least $137,831 | at least 148 | 3 of 8 |
| Xultophy | Suppressed | Suppressed | 5 of 5 |
By quarter, 2025
| Q1 2025 | at least $18,694,814 | at least 16,349 | 21 of 66 |
| Q2 2025 | at least $21,167,723 | at least 18,419 | 22 of 66 |
| Q3 2025 | at least $21,253,651 | at least 18,329 | 23 of 71 |
| Q4 2025 | at least $20,752,207 | at least 17,842 | 18 of 76 |
By quarter, 2026 (posted so far)
| Q1 2026 | at least $24,907,445 | at least 19,396 | 27 of 88 |
The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:
“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”
Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”
CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.
Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.
Sources
- CMS Medicaid State Drug Utilization Data (Medicaid.gov)
- State Drug Utilization Data 2020 (data.medicaid.gov)
- State Drug Utilization Data 2021 (data.medicaid.gov)
- State Drug Utilization Data 2022 (data.medicaid.gov)
- State Drug Utilization Data 2023 (data.medicaid.gov)
- State Drug Utilization Data 2024 (data.medicaid.gov)
- State Drug Utilization Data 2025 (data.medicaid.gov)
- State Drug Utilization Data 2026 (data.medicaid.gov)
Records last pulled Nov 15, 2026. Every entry links to the original public record.